Euronews is no longer accessible on Internet Explorer. This browser is not updated by Microsoft and does not support the last technical evolutions. We encourage you to use another browser, such as Edge, Safari, Google Chrome or Mozilla Firefox.
BREAKING NEWS

Pharma industry returns on R&D investment hit 9-year low

Pharma industry returns on R&D investment hit 9-year low
FILE PHOTO: Used blister packets that contained medicines, tablets and pills are seen, in this picture illustration taken June 30, 2018. REUTERS/Russell Boyce -
Copyright
Russell Boyce(Reuters)
Euronews logo
Text size Aa Aa

LONDON (Reuters) - The cost of developing a new drug has nearly doubled since 2010 and the world's 12 biggest drugmakers are making the lowest return on their R&D investments in nine years, according to Deloitte.

An annual survey of the economics of pharma research and development (R&D) by the consultancy found that despite a steady flow of new medicines reaching global markets, the 12 drugmakers' average return on their R&D fell to 1.9 percent this year, from 3.7 percent a year ago.

The average cost of bringing a new medicine to market is now $2.18 billion, up from $1.19 billion back in 2010.

Yet forecast peak sales for new medicines have halved over the same period to $408 million on average - a decline that reflects a growing focus on relatively small targeted patient groups, leading to multiple niche treatments.

"Despite the launch of many successful products, growing development costs and regulatory constraints are making it more difficult than ever for companies to redeem their R&D investment," said Deloitte consulting partner Colin Terry.

Overall, R&D returns are down by 8.2 percentage points since 2010, when they stood at 10.1 percent.

A group of younger and more specialised biotech companies analysed by Deloitte fared a lot better, with average returns of 9.3 percent, although this was still down from 12.5 percent in 2017.

The 12 big drugmakers tracked by Deloitte are Pfizer <PFE.N>, Roche <ROG.S>, Novartis <NOVN.S>, Sanofi <SASY.PA>, GlaxoSmithKline <GSK.L>, Johnson & Johnson <JNJ.N>, AstraZeneca <AZN.L>, Merck & Co <MRK.N>, Eli Lilly <LLY.N>, Bristol-Myers Squibb <BMY.N>, Takeda <4502.T> and Amgen <AMGN.O>.

The four biotech companies are Biogen <BIIB.O>, Celgene <CELG.O>, Gilead Sciences <GILD.O> and AbbVie <ABBV.N>.

(Reporting by Ben Hirschler; Editing by Susan Fenton)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on euronews.com for a limited time.